Welcome to our dedicated page for Bachem Holding news (Ticker: BCHMY), a resource for investors and traders seeking the latest updates and insights on Bachem Holding stock.
Bachem Holding AG reports company developments tied to its peptide and oligonucleotide development and manufacturing business for pharmaceutical and biotechnology customers worldwide. News commonly covers sales trends in CMC Development and Research & Specialties, manufacturing capacity projects such as the Bubendorf Building K expansion, and site activity in Europe, the United States and Asia.
Recurring updates also include financing arrangements for growth initiatives, Annual General Meeting actions, dividend approvals, sustainability and remuneration votes, and changes to the Corporate Executive Committee. The company is headquartered in Switzerland and is listed on the SIX Swiss Exchange.
Bachem (OTC: BCHMY; SIX: BANB) reported first-half 2026 sales of CHF 326.4 million, up 4.3% year-on-year (+7.3% in local currencies). EBITDA declined 9.0% to CHF 82.8 million, with margin falling to 25.4%, mainly due to expected ramp-up costs for the new large-scale facility Building K.
Net income edged up to CHF 50.3 million (+0.3%). Clinical CMC Development sales grew 35.4% to CHF 167.5 million, while Commercial API sales fell 21.0% to CHF 133.0 million. Bachem invested CHF 148.4 million in capacity in H1 and plans CHF 350–400 million in 2026, plus a >CHF 500 million Sisslerfeld site. The company guides for 2026 local-currency sales growth of 35–40% and an EBITDA margin in the low thirties, and appointed Boris Corpataux as Chief Commercial Officer effective August 1, 2026.
Bachem (OTC: BCHMY) plans to build a large-scale peptide production facility in Sisslerfeld (Eiken, Switzerland) as part of a strategic collaboration. According to Bachem, the total investment in this greenfield project will exceed CHF 500 million, supported by pre-payments and long-term supply commitments for large peptide volumes.
Commercial production at the new Sisslerfeld site is expected to start in 2030. Bachem says the agreement improves planning security beyond 2030 and helps coordinate capacity expansion across its global manufacturing network for peptides and oligonucleotides, which includes sites in Switzerland, the US and the UK.
Bachem Holding (OTC:BCHMY) will host a Capital Markets Day on 26 November 2026 at The Circle Convention Center, Hyatt Regency Zurich Airport, with a virtual option. The hybrid event will cover strategic priorities, business outlook, and key developments. A detailed invitation will follow.
Bachem (OTC: BCHMY) announced that Chief Commercial Officer Torsten Wöhr will leave the company and that CEO Anne-Kathrin Stoller will assume CCO duties in addition to her CEO role effective May 25, 2026. The company thanked Wöhr for his contributions to the oligonucleotide and peptide businesses and emphasized continuity in customer relationships during the transition.
Bachem (SIX: BANB) held its Annual General Meeting 2026 where shareholders approved all board proposals. A dividend of CHF 0.90 per share was approved, payable on May 6, 2026; last trading day with entitlement is April 30, 2026 and shares trade ex-dividend as of May 4, 2026.
Attendance was 78.3% of 74,977,940 eligible shares. Board members were re-elected; Helma Wennemers was newly elected Chair of the Compensation Committee. Forvis Mazars SA, Zurich was appointed auditor for 2026. A full list of resolutions and the financial calendar were published.
Bachem (OTC: BCHMY) closed a CHF 500 million revolving credit facility with a five-year maturity and a non-committed option to increase by CHF 150 million. UBS Switzerland AG acted as lead arranger and agent with a consortium of domestic and international banks. The financing refinances existing bilateral credit lines and is intended to support Bachem's strategic growth initiatives while strengthening operational and financial flexibility.
Bachem (OTC: BCHMY) reported group sales of CHF 695.1 million in 2025, up 14.8% (+19.2% in local currencies), and EBITDA of CHF 214.7 million (+21.8%), yielding an EBITDA margin of 30.9% (adjusted 28.6%).
The board proposes raising the dividend to CHF 0.90 per share. Investments totaled CHF 332.6 million in 2025 and CAPEX above CHF 400 million is planned for 2026. Outlook: sales growth of 35–45% in LC and an EBITDA margin in the low thirties (LC) for 2026.
Bachem (SIX: BANB) announced that Anne-Kathrin Stoller will become CEO effective January 1, 2026, succeeding Thomas Meier, who is leaving after more than thirty years with the company and nearly six years as CEO.
Stoller has worked at Bachem since 2006, has held roles including Head of Business Development & Sales Europe, Chief Marketing Officer, and since 2022 has led Bachem Americas as Chief Operating Officer Americas; she holds a doctorate in bioorganic chemistry from the University of Basel.
Bachem (OTC:BCHMY) reported progress on two capacity projects: the inspection and planned start-up of Building K in Bubendorf and an adjacent property acquisition in Vista, California. Local regulators inspected Building K and signaled no delays; Bachem expects first GMP batches in 2025 with commercial ramp in 2026 while remaining construction continues. In the US, the company plans to convert the Vista property to production and announced an overall ~USD 250 million investment for 2026–2030 to expand Vista capacity and modernize Torrance.
Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025. Van Hees, currently serving as COO Europe, will join the Corporate Executive Committee and oversee Bachem's worldwide manufacturing network.
Van Hees joined Bachem in 2024 from Pharma Resource Group and brings over 25 years of manufacturing leadership experience from Johnson & Johnson and Janssen. He will take over the COO responsibilities from CEO Thomas Meier, who had been handling both roles since 2023. The new COO holds a PhD in Chemistry and an MBA from KU Leuven.